摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

C-(4-chlorophenyl)-C-[1-(1H-pyrrolo[2,3-b]pyridin-4-yl)piperidin-4-yl]methylamine | 885594-29-6

中文名称
——
中文别名
——
英文名称
C-(4-chlorophenyl)-C-[1-(1H-pyrrolo[2,3-b]pyridin-4-yl)piperidin-4-yl]methylamine
英文别名
4-Piperidinemethanamine,a-(4-chlorophenyl)-1-(1h-pyrrolo[2,3-b]pyridin-4-yl)-;(4-chlorophenyl)-[1-(1H-pyrrolo[2,3-b]pyridin-4-yl)piperidin-4-yl]methanamine
C-(4-chlorophenyl)-C-[1-(1H-pyrrolo[2,3-b]pyridin-4-yl)piperidin-4-yl]methylamine化学式
CAS
885594-29-6
化学式
C19H21ClN4
mdl
——
分子量
340.856
InChiKey
PRPNDHHOYWARPB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    24
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    57.9
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    C-(4-chlorophenyl)-C-[1-(1H-pyrrolo[2,3-b]pyridin-4-yl)piperidin-4-yl]methylamine 生成 (R)-C-(4-chlorophenyl)-C-[1-(1H-pyrrolo[2,3-b]pyridin-4-yl)piperidin-4-yl]methylamine
    参考文献:
    名称:
    WO2006/46023
    摘要:
    公开号:
  • 作为产物:
    参考文献:
    名称:
    通过片段加工鉴定4-(4-氨基哌啶-1-基)-7H-吡咯并[2,3-d]嘧啶作为蛋白激酶B的选择性抑制剂。
    摘要:
    基于片段的筛选确定7-氮杂吲哚为蛋白激酶B抑制剂支架。使用抑制剂-PKA-PKB嵌合体复合物的反复结晶学方法对片段进行精细加工,可有效指导化合物效力和选择性的提高,从而鉴定出纳摩尔级的6-(哌啶-1-基)嘌呤,4-(哌啶-1-基)纳摩尔。 )-7-氮杂吲哚和PKBbeta的4-(哌啶-1-基)吡咯并[2,3-d]嘧啶抑制剂具有抗增殖活性,并在细胞中表现出途径抑制作用。在包含4-氨基甲基哌啶和含4-氨基哌啶的分子之间观察到结合模式的差异。用4-氨基哌啶衍生物观察到PKB对PKA的选择性,大多数PKB选择性抑制剂(30倍)显示出PKA和PKA-PKB嵌合体之间的结合构象显着不同。
    DOI:
    10.1021/jm701437d
点击查看最新优质反应信息

文献信息

  • Pharmaceutical Compounds
    申请人:Davies Thomas Glanmor
    公开号:US20090253718A1
    公开(公告)日:2009-10-08
    The invention provides a compound having the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR 5 ; J 1 -J 2 is N═C(R 6 ), (R 7 )C═N, (R 8 )N—C(O), (R 8 ) 2 C—C(O), N═N or (R 7 )C═C(R 6 ); A is an optionally substituted saturated C 1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between R 1 and NR 2 R 3 and a maximum chain length of 4 atoms extending between E and NR 2 R 3 , one of the carbon atoms in the linker group being optionally replaced by oxygen or nitrogen; E is a monocyclic or bicyclic carbocyclic or heterocyclic group or an acyclic group X-G wherein X is CH 2 , O, S or NH and G is a C 1-4 alkylene chain wherein one of the carbon atoms is optionally replaced by O, S or NH; R 1 is hydrogen or an aryl or heteroaryl group; R 2 and R 3 are each hydrogen, optionally substituted C 1-4 hydrocarbyl or optionally substituted C 1-4 acyl; or NR 2 R 3 forms an imidazole group or a saturated monocyclic heterocyclic group having 4-7 ring members; or NR 2 R 3 and A together form a saturated monocyclic heterocyclic group having 4-7 ring members which is optionally substituted by C 1-4 alkyl; or NR 2 R 3 and the adjacent carbon atom of linker group A together form a cyano group; or R 1 , A and NR 2 R 3 together form a cyano group; and R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and various substituents as defined in the claims, wherein the compound is for use in: (a) the treatment or prophylaxis of a disease or condition in which the modulation (e.g. inhibition) of ROCK kinase or protein kinase p70S6K is indicated; and/or (b) the treatment of a subject or patient population in which the modulation (e.g. inhibition) of ROCK kinase or protein kinase p70S6K is indicated.
    本发明提供了具有以下式子(I)的化合物或其盐,溶剂化物,互变异构体或N-氧化物,其中T为N或CR5; J1-J2为N═C(R6),(R7)C═N,(R8)N—C(O),(R8)2C—C(O),N═N或(R7)C═C(R6); A为最大链长为5个原子的选择性取代的饱和C1-7碳氢链连接基,在R1和NR2R3之间延伸,最大链长为4个原子,在E和NR2R3之间延伸,链连接基中的一个碳原子可以被氧或氮取代; E为单环或双环的碳环或杂环基团或一个无环的X-G基团,其中X为CH2,O,S或NH,G为一个C1-4烷基链,其中一个碳原子可以被O,S或NH取代; R1为氢或芳基或杂环基团; R2和R3分别为氢,选择性取代的C1-4烃基或选择性取代的C1-4酰基; 或NR2R3形成咪唑基团或具有4-7个环成员的饱和单环杂环基团; 或NR2R3和A一起形成一个被C1-4烷基取代的饱和单环杂环基团; 或NR2R3和链连接基A的相邻碳原子一起形成氰基团; 或R1,A和NR2R3一起形成氰基团; R4,R5,R6,R7和R8各自独立地选择氢和各种在权利要求中定义的取代基,其中该化合物用于:(a)治疗或预防调节ROCK激酶或蛋白激酶p70S6K所示的疾病或情况; 和/或(b)治疗调节ROCK激酶或蛋白激酶p70S6K所示的受试者或患者人群。
  • Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors
    申请人:Berdini Valerio
    公开号:US20090099213A1
    公开(公告)日:2009-04-16
    The invention provides a compound for use in the prophylaxis or treatment of a disease state or condition mediated by protein kinase B, the compound having the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR 5 ; J 1 -J 2 is N═C(R 6 ), (R 7 )C═N, (R 8 )N—C(O), (R 8 ) 2 C—C(O), N═N or (R 7 )C═C(R 6 ); A is an optionally substituted saturated C 1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between R 1 and NR 2 R 3 and a maximum chain length of 4 atoms extending between E and NR 2 R 3 , one of the carbon atoms in the linker group being optionally replaced by oxygen or nitrogen; E is a monocyclic or bicyclic carbocyclic or heterocyclic group or an acyclic group X-G wherein X is CH 2 , O, S or NH and G is a C 1-4 alkylene chain wherein one of the carbon atoms is optionally replaced by O, S or NH; R 1 is hydrogen or an aryl or heteroaryl group; R 2 and R 3 are each hydrogen, optionally substituted C 1-4 hydrocarbyl or optionally substituted C 1-4 acyl; or NR 2 R 3 forms an imidazole group or a saturated monocyclic heterocyclic group having 4-7 ring members; or NR 2 R 3 and A together form a saturated monocyclic heterocyclic group having 4-7 ring members which is optionally substituted by C 1-4 alkyl; or NR 2 R 3 and the adjacent carbon atom of linker group A together form a cyano group; or R 1 , A and NR 2 R 3 together form a cyano group; and R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and various substituents as defined in the claims.
    本发明提供了一种化合物,可用于预防或治疗由蛋白激酶B介导的疾病状态或病况,该化合物具有以下式(I)或其盐,溶剂化合物,互变异构体或N-氧化物,其中T为N或CR5;J1-J2为N═C(R6),(R7)C═N,(R8)N—C(O),(R8)2C—C(O),N═N或(R7)C═C(R6);A为一个可选取代的饱和C1-7碳链连接基团,其最大链长为5个原子,延伸在R1和NR2R3之间,并且最大链长为4个原子,延伸在E和NR2R3之间,连接基团中的一个碳原子可被氧或氮取代;E为单环或双环碳环或杂环基团或一个无环基团X-G,其中X为CH2,O,S或NH,G为C1-4烷基链,其中一个碳原子可被O,S或NH取代;R1为氢或芳基或杂芳基团;R2和R3分别为氢,可选取代的C1-4烃基或可选取代的C1-4酰基;或NR2R3形成咪唑基团或具有4-7个环成员的饱和单环杂环基团;或NR2R3和A一起形成具有4-7个环成员的饱和单环杂环基团,该基团可选取代为C1-4烷基;或NR2R3和连接基团A的相邻碳原子一起形成氰基团;或R1,A和NR2R3一起形成氰基团;R4,R5,R6,R7和R8各自独立地选择氢和各种定义中定义的取代基。
  • WO2007/125315
    申请人:——
    公开号:——
    公开(公告)日:——
  • Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
    申请人:Thompson Neil Thomas
    公开号:US20090082370A1
    公开(公告)日:2009-03-26
    The invention provides a combination for use as a protein kinase B inhibitor, the combination comprising (or consisting essentially of) an ancillary compound and: (I) a compound of the formula: or salts, solvates, tautomers or N-oxides thereof, wherein R 1 , Q 1 , Q 2 , E, G, T, R 4 , J 1 and J 2 are as defined in the claims; or (II) a compound having the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein R 1 , R 2 , R 3 , R 4 , E, A, T, J 1 and J 2 are as defined in the claims.
  • [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
    申请人:ASTEX THERAPEUTICS LTD
    公开号:WO2007125315A2
    公开(公告)日:2007-11-08
    [EN] The invention provides a compound having the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N=C(R6), (R7)C=N, (R8)N-C(O), (R8)2C-C(O), N=N or (R7)C=C(R6); A is an optionally substituted saturated C1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, one of the carbon atoms in the linker group being optionally replaced by oxygen or nitrogen; E is a monocyclic or bicyclic carbocyclic or heterocyclic group or an acyclic group X-G wherein X is CH2, O, S or NH and G is a C1-4 alkylene chain wherein one of the carbon atoms is optionally replaced by O, S or NH; R1 is hydrogen or an aryl or heteroaryl group; R2 and R3 are each hydrogen, optionally substituted C1-4 hydrocarbyl or optionally substituted C1-4 acyl; or NR2R3 forms an imidazole group or a saturated monocyclic heterocyclic group having 4-7 ring members; or NR2R3 and A together form a saturated monocyclic heterocyclic group having 4-7 ring members which is optionally substituted by C1-4 alkyl; or NR2R3 and the adjacent carbon atom of linker group A together form a cyano group; or R1, A and NR2R3 together form a cyano group; and R4, R5, R6, R7 and R8 are each independently selected from hydrogen and various substituents as defined in the claims, wherein the compound is for use in: (a) the treatment or prophylaxis of a disease or condition in which the modulation (e.g. inhibition) of ROCK kinase or protein kinase p70S6K is indicated; and/or (b) the treatment of a subject or patient population in which the modulation (e.g. inhibition) of ROCK kinase or protein kinase p70S6K is indicated.
    [FR] L'invention concerne un composé de formule (I) ou des sels, solvates, tautomères ou N-oxydes de ce composé. Dans la formule (I), T représente N ou CR5, J1-J2 représente N=C(R6), (R7)C=N, (R8)N-C(O), (R8)2C-C(O), N=N ou (R7)C=C(R6), A représente un groupe de liaison hydrocarbure C1-7 saturé éventuellement substitué ayant une longueur de chaîne maximale de 5 atomes entre R1 et NR2R3 et une longueur de chaîne maximale de 4 atomes entre E and NR2R3, l'un des atomes de carbone du groupe de liaison étant éventuellement remplacé par oxygène ou azote, E représente un groupe carbocyclique ou hétérocyclique monocyclique ou bicyclique ou un groupe acyclique X-G dans lequel X représente CH2, O, S ou NH et G est une chaîne alkylène C1-4 dans laquelle l'un des atomes de carbone est éventuellement remplacé par O, S ou NH, R1 représente hydrogène ou un groupe aryle ou hétéroaryle, R2 et R3 représentent chacun hydrogène, hydrocarbyle C1-4 éventuellement substitué ou acyle C1-4 éventuellement substitué ou bien NR2R3 représente un groupe imidazole ou un groupe hétérocyclique monocyclique saturé ayant 4 à 7 chaînons cycliques ou bien NR2R3 et A forment ensemble un groupe hétérocyclique monocyclique saturé ayant 4 à 7 chaînons cycliques et étant éventuellement substitué par alkyle C1-4 ou bien NR2R3 et l'atome de carbone adjacent du groupe de liaison A forment ensemble un groupe cyano ou bien R1, A et NR2R3 forment ensemble un groupe cyano, et R4, R5, R6, R7 et R8 sont chacun sélectionnés indépendamment l'un de l'autre parmi hydrogène et divers substituants comme défini dans les revendications. Le composé selon l'invention est utilisable (a) dans le traitement ou la prophylaxie d'une maladie ou d'une affection dans laquelle la modulation (par exemple, l'inhibition) de la kinase ROCK ou de la protéine kinase p70S6K est indiquée et/ou (b) dans le traitement d'une population de sujets ou de patients dans laquelle la modulation (par exemple, l'inhibition) de la kinase ROCK ou de la protéine kinase p70S6K est indiquée.
查看更多

同类化合物

(4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 骆驼蓬酸 顺-六氢-1H-吡咯并[3,2-B]吡啶-4(2H)-羧酸叔丁基酯 螺哌啶-4,3’-3H吡咯并[2,3-b]吡啶-2’(1’H)-酮 螺[哌啶-4,3'-吡咯并[2,3-B]吡啶]-2'(1'H)-酮盐酸盐 莫西沙星杂质69 苹果酸法米替尼 苯乙胺,a,4-二甲基-b-苯基- 苄基-11氢吡咯并[3,4-B]吡啶 罗沙布林 甲基6-甲酰基-1-甲基-1H-吡咯并[3,2-b]吡啶-2-羧酸酯 甲基5-氰基-1H-吡咯并[2,3-b]吡啶-2-羧酸酯 甲基1H-吡咯并[2,3-B]吡啶-5-甲酸酯 甲基-1-甲氧基-4-吡咯并[3,2-c]吡啶 甲基 5-硝基-1H-吡咯并[2,3-B]吡啶-2-羧酸 环戊二烯并[4,5]吡咯并[2,3-B]吡啶,5,6,7,8-四氢 氧代-(1H-吡咯并[2,3-b]吡啶-3-基)-乙酸甲酯 培西达替尼盐酸盐 培西达替尼 吲嗪 吲哚嗪-6-羧酸乙酯 吲哚嗪-3-甲腈 吲哚嗪-2-羧酸甲酯 吲哚嗪-2-羧酸 叔丁基八氢-1H-吡咯并[2,3-c]吡啶-6-羧酸盐 叔丁基5-溴-7-氯-3-碘-1H-吡咯并[2,3-c]吡啶-1-羧酸盐 叔丁基5-溴-7-氯-1H-吡咯并[2,3-c]吡啶-1-羧酸盐 叔丁基3-甲酰基-5-甲基-1H-吡咯并[2,3-b]吡啶-1-羧酸盐 叔丁基3-(3-羟丙基-1-炔基)-5-甲基-1H-吡咯并[2,3-b]吡啶-1-羧酸盐 叔丁基(5-甲基-1H-吡咯并[2,3-b]吡啶-3-基)氨基甲酸酯 叔丁基((5-氟代-1H-吡咯并[2,3-b]吡啶-4-基)甲基氨基甲酸酯 反式-六氢-1H-吡咯并[3,4-C]吡啶-5(6H)-羧酸叔丁酯 化合物 T28221 八氢吡咯并[3.4-b]吡啶-1-羧酸叔丁酯 八氢吡咯并[3,4-b]吡啶 八氢-吡咯[3,4-C]吡啶-2-甲酸叔丁酯 八氢-6-(苯基甲基)-1H-吡咯并[3,4-b]吡啶-1-羧酸 1,1-二甲基乙酯 八氢-1H-吡咯并[3,4-C]吡啶 二苯基(吡咯并[2,3-b]吡啶-1-基)膦 二乙基1H-吡咯并[2,3B]吡啶-2,6-二甲酸基酯 乙基7-氯-3-甲基-1H-吡咯并[3,2-b]吡啶-2-甲酸基酯 乙基7-氮杂吲哚-4-羧酸酯 乙基4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-吡咯并[2,3-b]吡啶-2-羧酸酯 乙基3-氨基-2-吲嗪羧酸酯 乙基1-乙基-1H-吡咯并[3,2-c]吡啶-6-羧酸酯 中氮茚-7-羧酸甲酯 中氮茚-6-羧酸 中氮茚-1-甲酸甲酯 中氮茚-1-甲酸 中氮茚,1-[[4-(3-溴丙氧基)苯基]磺酰]-2-乙基-